Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
Clinical trial NCT02559622 · COMPLETED
Trial details
- NCT number
- NCT02559622
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-04-01
- Primary completion
- 2016-04-01
- Enrollment
- 151
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.